EU approve Gedeon’s novel antipsychotic for schizophrenia
European regulators have approved Gedeon Richter’s novel antipsychotic Reagila as a new option for the treatment of patients with schizophrenia. In clinical trials the drug, a potent dopamine D3/D2 receptor partial agonist atypical antipsychotic, significantly improved symptoms of the condition and reduced the risk of relapse by 55% when compared to the placebo.